HEALTH CARE:
PHARMACEUTICALS
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Entremed develops oncology and anti-inflammatory drugs that target disease cells directly and the blood vessels that nourish them. Panzem (2-methoxyestradiol or 2ME2), EntreMed's lead drug candidate, was in clinical trials for cancer in March 2005, and in preclinical development for other indications.
| Market Cap | 239.212 Million | Shares Outstanding | 123.944 Million | Avg 30-day Volume | 490.586 Thousand |
| P/E Ratio | Dividend Yield | EPS | -0.48 | ||
| Price/Sales | 30.963 | Price cash flow ratio | Price free cash flow ratio | -11.4 | |
| Book Value | 0.57 | Price to Tangible Book | 3.58 | Alpha | 0.02 |
| Short Interest Ratio | % Short Interest to Float | R-squared | 0.030414 | ||
| BETA | 0.918667 | 52-week High/Low | 3.82 / 1.15 | Stddev | 0.22664 |
| Q1 2020 | All Institutions | Hedge Funds 1 |
|---|---|---|
| Filers who had this stock in their top 10: | 0 | 0 (0.0%) |
| 13F Filers holding this stock: | 60 | 11 (0.72%) |
| Aggregate 13F shares on 03/31/2020: | 13.769 Million | 3.673 Million |
| Aggregate 13F shares on 12/31/2019: | 20.44 Million | 3.242 Million |
| Percent change: | -32.64% | 13.30% |
| Funds creating new positions: | 11 | 3 |
| Funds Adding to an existing position: | 22 | 6 |
| Funds closing out their position: | 5 | |
| Funds reducing their position: | 15 | 1 |
| 1 hedge funds as identified by whalewisdom.com through public filings. | ||
| CASI Pharmaceuticals Inc Chart by YCharts | |
| Yahoo! Finance | finviz |
| SEC Web Site | SEC DEF 14A Filings |
Please sign in first
4.2 Million total shares from 3 transactions
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
HE WEI-WU CHAIRMAN AND CEO |
|
12,809,942 | 2020-07-22 | 9 |
|
ZHANG LARRY PRESIDENT |
|
20,153 | 2020-07-22 | 2 |
|
0 | 2020-07-20 | 1 | |
|
0 | 2020-06-16 | 1 | |
|
0 | 2020-06-16 | 1 | |
|
0 | 2020-06-16 | 1 | |
|
0 | 2020-06-16 | 1 | |
|
69,713 | 2020-06-09 | 0 | |
|
473,461 | 2020-06-05 | 0 | |
|
9,087,888 | 2019-12-30 | 1 | |
|
ZUKIWSKI ALEXANDER A CHIEF MEDICAL OFFICER |
|
0 | 2019-12-15 | 1 |
|
0 | 2019-06-20 | 0 | |
|
10,047,675 | 2019-04-02 | 0 | |
|
HU CYNTHIA W. COO, GEN COUNSEL & SECRETARY |
|
0 | 2019-01-29 | 0 |
|
TIANJIN JINGRAN MANAGEMENT CENTER (LIMITED PARTNERSHIP) |
|
10,198,518 | 2018-11-13 | 0 |
|
CHI GEORGE CHIEF FINANCIAL OFFICER |
|
0 | 2018-09-28 | 0 |
|
7,756,801 | 2018-09-11 | 0 | |
|
CAPITELLI SARA B VP FIN & PRINCIPAL ACCOUNT OFF |
|
0 | 2018-07-12 | 0 |
|
0 | 2018-06-29 | 0 | |
|
IDG-ACCEL CHINA GROWTH FUND III L.P. IDG-ACCEL CHINA III INVESTORS L.P. IDG-ACCEL CHINA GROWTH FUND III ASSOCIATES L.P. IDG-ACCEL CHINA GROWTH FUND GP III ASSOCIATES LTD. |
|
9,773,370 | 2018-03-21 | 0 |
|
REN KEN CHIEF FINANCIAL OFFICER |
|
1,080,000 | 2017-01-05 | 0 |
|
TIANJIN JINGRAN MANAGEMENT CENTER (LIMITED PARTNERSHIP) |
|
8,498,765 | 2016-06-24 | 0 |
|
0 | 2016-03-02 | 0 | |
|
SAGLIO DANE R CHIEF FINANCIAL OFFICER |
|
0 | 2014-04-16 | 0 |
|
0 | 2013-05-30 | 0 | |
|
0 | 2013-05-30 | 0 | |
|
|
0 | 2012-12-11 | 0 | |
|
0 | 2012-03-12 | 0 | |
|
0 | 2012-01-23 | 0 | |
|
SIDOR CAROLYN F V.P. AND CHIEF MEDICAL OFFICER |
|
0 | 2011-01-05 | 0 |
|
BRAY MARK R VICE PRESIDENT, RESEARCH |
|
0 | 2011-01-05 | 0 |
|
WEHMEIR-DAVIS KATHY PRINCIPAL ACCOUNTING OFFICER |
|
0 | 2009-01-27 | 0 |
|
BLISS THOMAS H JR SVP, BUS. & CORP. DEVELOPMENT |
|
0 | 2008-06-18 | 0 |
| Reporting Owners | Transaction Date | Transaction Code | Shares | Share Price | Acquired or Disposed | Shares Owned Following Transaction | Combined shares owned after filing | Direct/Indirect Ownership | 10b-5 |
|---|---|---|---|---|---|---|---|---|---|
|
HE WEI-WU - Director - Officer - > 10% Owner CHAIRMAN AND CEO |
2020-07-22 | P | 2,952,426 | $1.90 | a | 4,836,523 | 12,809,942.00 | direct | |
| 2020-07-22 | P | 20,153 | $1.90 | a | 20,153 | 20,153.00 | direct | ||
|
HE WEI-WU - Director - Officer - > 10% Owner CHAIRMAN AND CEO see footnote |
2020-07-22 | P | 1,200,000 | $1.90 | a | 7,532,347 | 12,809,942.00 | indirect | |
| 2020-06-16 | A | 61,257 | a | 61,257 | 0.00 | direct | |||
| 2020-06-16 | A | 70,400 | a | 70,400 | 0.00 | direct | |||
| 2020-06-16 | A | 68,800 | a | 68,800 | 0.00 | direct | |||
| 2020-06-16 | A | 67,429 | a | 67,429 | 0.00 | direct | |||
| 2020-06-16 | A | 68,800 | a | 68,800 | 0.00 | direct |
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
